Hagenbeek, A <br/><br/>
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Jan 1998 
 - 41-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.1998.16.1.41  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cyclophosphamide--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--therapeutic use<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Neoplasm, Residual<br/>Prednisone--administration & dosage<br/>Prospective Studies<br/>Recombinant Proteins<br/>Remission Induction<br/>Survival Analysis<br/>Vincristine--administration & dosage